PT - JOURNAL ARTICLE AU - Tlali, Mpho AU - Scheibe, Andrew AU - Ruffieux, Yann AU - Cornell, Morna AU - Wettstein, Anja E AU - Egger, Matthias AU - Davies, Mary-Ann AU - Maartens, Gary AU - Johnson, Leigh F AU - Haas, Andreas D TI - Diagnosis and treatment of opioid use disorder in a South African private sector medical insurance AID - 10.1101/2022.04.28.22274253 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.28.22274253 4099 - http://medrxiv.org/content/early/2022/04/28/2022.04.28.22274253.short 4100 - http://medrxiv.org/content/early/2022/04/28/2022.04.28.22274253.full AB - Background The use of opioids is increasing globally, but data on opioid use disorder (OUD) in South Africa are scarce. This study examines the incidence of diagnosed OUD, opioid agonist use, and excess mortality among persons with OUD in South Africa’s private healthcare sector.Methods We conducted a cohort study of beneficiaries (≥ 11 years) of a South African medical insurance scheme using reimbursement claims from Jan 1, 2011, to Jul 1, 2020. Beneficiaries were classified as having OUD if they received opioid agonists (buprenorphine or methadone), an ICD-10 F11 diagnosis for a mental and behavioural disorder due to opioid use, or an ICD-10 T40 diagnosis for opioid poisoning. We calculated adjusted hazard ratios (aHR) for factors associated with OUD, estimated the cumulative incidence of opioid agonist use after receiving an ICD-10 F11 diagnosis, and examined excess mortality among beneficiaries with OUD.Results Of 1,251,458 beneficiaries, 1,313 (0.1%) had OUD. Between 2011 and 2020, the incidence of OUD increased by 12% (95% CI 9%-14%) per year. Men, young adults in their twenties, and beneficiaries with co-morbid mental health or other substance use disorders were at increased risk of OUD. The cumulative incidence of opioid agonist use was 10.6% (95% CI 8.3-13.2) at 3 years after receiving an F11 diagnosis. After adjusting for age, sex, year, medical insurance coverage, and population group, OUD was associated with an increased risk of mortality (aHR 2.29, 95% CI 1.85-2.82). OUD was associated with a 7.63-year shorter life expectancy (95% CI 4.08-10.70).Conclusions The incidence of patients diagnosed with or treated for OUD in the private sector is increasing rapidly. People with OUD in the private sector are a vulnerable population with substantial psychiatric comorbidity who often die prematurely. Evidence-based management of OUD is urgently needed to improve the health outcomes of people with OUD.Competing Interest StatementNoneFunding StatementResearch reported in this publication was supported by the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases and the Fogarty International Center under Award Number U01AI069924. AH was supported by an Ambizione fellowship (193381) and ME by special project funding (207285) from the Swiss National Science Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000. We obtained data from the International Epidemiology Database to Evaluate AIDS (IeDEA) Southern Africa collaboration (Chammartin et al., 2020). IeDEA Southern Africa collects routine clinical and administrative data for HIV-positive and HIV-negative children and adults in six Southern African countries. All programmes participating in IeDEA have ethics approval to contribute de-identified data to the IeDEA Data Centre. Beneficiaries of the medical insurance scheme or their guardians provided consent for their data to be used in research. The Human Research Ethics Committee of the University of Cape Town, South Africa (reference number 084/2006), and the Cantonal Ethics Committee of the Canton of Bern, Switzerland (150/14, PB_2016-00273) granted permission to analyse data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data were obtained from the IeDEA-SA. Data cannot be made available online because of legal and ethical restrictions. To request data, readers may contact IeDEA-SA for consideration by filling out the online form available at https://www.iedea-sa.org/contact-us/.